Pharmaceutical Technology

MARCH 23, 2023

The drug is currently licensed in combination with chemotherapy for patients with classical Hodgkin lymphoma, both as frontline therapy and for those at risk of progressing or having progressed following stem cell transplantation. compound annual growth rate (CAGR) according to Pfizer’s risk-adjusted projection.

Chemotherapy 59

Chemotherapy Compounding FDA 59

Pharmaceutical Technology

AUGUST 12, 2022

By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. The standard first-line treatment for DLBCL is a chemotherapy regimen, alongside the monoclonal antibody rituximab. Overall, the global CAR-T cell market for all indications was worth $1.7 billion by the end of 2022.

Immunization 52

Immunization Chemotherapy Compounding 52

Pharmaceutical Technology

FEBRUARY 13, 2023

This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. GlobalData’s analyst consensus forecast database estimates peak annual sales for ARV-110 of $325 million in 2028.

Dosage 59

Dosage Chemotherapy Compounding Immunization 59